Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nepal Healthcare Times.
Press releases published on August 4, 2025
Atavistik Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ATV-1601 in Patients with AKT1 E17K-mutant Solid Tumors
GlobeNewswire
·
August 4, 2025
ATV-1601 is a first-in-class allosteric selective inhibitor of AKT1 E17K Pan-AKT inhibitors offer limited efficacy for patients with AKT1 E17K-driven mutant tumors due to insufficient inhibition of the AKT1 E17K mutation and AKT2-driven tolerability issues …
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results
GlobeNewswire
·
August 4, 2025
$96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatment of DEB patients from birth Strong balance sheet, ending the quarter with $820.8 million in cash and investments PITTSBURGH, Aug. 04, …
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025
GlobeNewswire
·
August 4, 2025
WATERTOWN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second quarter …
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 4, 2025
—Q2 2025 ORLADEYO net revenue of $156.8 million (+45 percent y-o-y)— —Q2 2025 operating profit of $29.8 million (+239 percent y-o-y); non-GAAP operating profit of $57.0 million (+160 percent y-o-y)— —Company makes additional $50 million paydown of term …
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
GlobeNewswire
·
August 4, 2025
WARREN, N.J., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Accumulus Synergy Spins Out Accumulus Technologies to Scale Proven Regulatory Platform and Accelerate Global Access to Therapies
GlobeNewswire
·
August 4, 2025
BURLINGAME, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- In a bold move to accelerate regulatory innovation and meet growing global demand, Accumulus Synergy, a nonprofit industry association, today announced the formation of Accumulus Technologies, a new …
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
GlobeNewswire
·
August 4, 2025
Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million Conference call to be held today, Monday, August 4, 2025, …
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
GlobeNewswire
·
August 4, 2025
BOSTON, Mass., and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have entered into a definitive merger …
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
GlobeNewswire
·
August 4, 2025
BOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have entered into a definitive merger agreement ( …
BioNTech veröffentlicht Ergebnisse für das zweite Quartal 2025 sowie Informationen zur Geschäftsentwicklung
GlobeNewswire
·
August 4, 2025
BioNTech treibt Onkologiestrategie voran, u.a. mit zwei bekanntgegeben Transaktionen, und setzt damit den Fokus auf die zwei tumorübergreifenden (Pan-Tumor-)Programme: mRNA-Krebsimmuntherapie-Kandidaten und BNT327, ein gegen PD-L11 und VEGF-A gerichteter …
BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter
GlobeNewswire
·
August 4, 2025
SUNNYVALE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provides the anticipated timing of regulatory …
Microbiotica Announces Completion of Recruitment in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients
GlobeNewswire
·
August 4, 2025
CAMBRIDGE, United Kingdom, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that patient recruitment is …
New Way to Take Iron: IBSA Launches Innovative Orally Dissolving Film Supplement That’s Gentle on the Stomach and Easy to Take
GlobeNewswire
·
August 4, 2025
WATFORD, United Kingdom, Aug. 04, 2025 (GLOBE NEWSWIRE) -- A new generation of vitamin supplementation has arrived in the UK. IBSA, the Swiss-based pharmaceutical company, has launched a groundbreaking Iron Orodispersible Film (ODF), a thin, fast- …